Market Cap 113.48B
Revenue (ttm) 48.19B
Net Income (ttm) 7.05B
EPS (ttm) N/A
PE Ratio 9.66
Forward PE 9.06
Profit Margin 14.64%
Debt to Equity Ratio 2.21
Volume 8,132,776
Avg Vol 10,812,666
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 63%
Beta 0.24
Analysts Sell
Price Target $62.88

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unres...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
PhantomZ
PhantomZ Jun. 10 at 9:14 PM
$TLTFF $MRK $PFE $BMY https://medicalxpress.com/news/2026-06-ultrasound-anticancer-molecule-deep-lung.html
0 · Reply
Fingerlickengood
Fingerlickengood Jun. 10 at 4:17 PM
$CDXS $MRK $ALNY $BMY I believe the importance of this during their 2026 USA TIDES presentation was completely overlooked by focusing on 'stereo chemistry'. While the 'stereochemistry' aspect is important, this capability sets the EcoSynthesis Platform WELL AHEAD of any other existing and competing technologies! This alone will make it king, and the industry standard! https://www.codexis.com/technical-content/controlling-stereochemistry/
0 · Reply
Woodman7
Woodman7 Jun. 10 at 1:15 PM
$BMY $JNJ $ABT $PFIZER.NSE Check this Clene news
0 · Reply
Quantumup
Quantumup Jun. 9 at 7:06 PM
Raymond James says that w/ unanimous board approval, it sees no reason the $NUVL and $GSK M&A deal would not close in a timely manner—it thinks GSK is paying a fair price. ⬇️Nuvalent to Market Perform from Outperform $NUVB $BMY
0 · Reply
Quantumup
Quantumup Jun. 9 at 5:41 PM
RBC Capital sees pot'l readthrough to $NUVB (Outperform; $20) after $NUVL - $GSK M&A deal. $BMY Here's what RBC Capital had to say in its note to investors: https://x.com/Quantumup1/status/2064401843447276017?s=20
0 · Reply
taxplanr
taxplanr Jun. 9 at 12:33 PM
$BNTX $MRNA $MRK $BMY do you know why RNA programming will never work even for cancer? https://www.instagram.com/reel/DZLfm1EybwI/?igsh=b2ZiaG9vOGs5MXd0
1 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Jun. 8 at 7:11 PM
$PFE continues to make steady progress on a number of fronts as product lines expand and grow. Position into on weakness imho. Sector still weak and many big names performing poorly today $BMY $REGN $AMGN $BIIB for a few, but number of undervalued big names with solid dividends to boot!
1 · Reply
focafoca99
focafoca99 Jun. 8 at 11:32 AM
$BMY introduced its new multiple myeloma awareness campaign with Mariska Hargitay. https://www.rapidticker.com/news/bmy-mariska-hargitay-partners-with-bristol-ed2008
0 · Reply
CaesarZane
CaesarZane Jun. 7 at 9:13 PM
$GOOG $BMY $XOM 🚀🚀🚀 https://youtu.be/uk632v0svsY
0 · Reply
OnlyFibs
OnlyFibs Jun. 6 at 5:36 PM
$BMY is executing a masterful pipeline pivot. While the Street is stuck in "patent cliff" rearview-mirror thinking, the ASCO 2026 data shows mezigdomide is an absolute beast in multiple myeloma (52% progression risk reduction!). This isn't a legacy play anymore; it's a focused oncology innovator building high-margin durability. 🔬 🐂 Bull Level: Reclaim $57.00 to confirm the breakout toward $60.00+. 🐻 Bear Level: $54.00 is the non-negotiable floor. #BMY #BristolMyers #Oncology #Biotech #hovdid
1 · Reply
Latest News on BMY
Bristol Myers says FDA accepts sNDA for Camzyos

2026-06-01T11:15:21.000Z - 9 days ago

Bristol Myers says FDA accepts sNDA for Camzyos


C4 Therapeutics jumps after Bristol Myers myeloma data

2026-05-29T15:51:38.000Z - 12 days ago

C4 Therapeutics jumps after Bristol Myers myeloma data

CCCC


Bristol Myers announces strategic agreement with Anthropic

2026-05-20T11:00:11.000Z - 21 days ago

Bristol Myers announces strategic agreement with Anthropic


Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

May 12, 2026, 2:35 AM EDT - 4 weeks ago

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up


Bristol-Myers Squibb Company Transcript: AGM 2026

May 5, 2026, 10:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Transcript: AGM 2026


Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026


Bristol-Myers Squibb Company Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Earnings release: Q1 2026


Bristol-Myers Squibb Company Slides: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Slides: Q1 2026


Bristol-Myers Squibb Company Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Bristol-Myers Squibb Company Quarterly report: Q1 2026


Bristol Myers Squibb Logs Higher Sales, Profit

Apr 30, 2026, 7:11 AM EDT - 5 weeks ago

Bristol Myers Squibb Logs Higher Sales, Profit


Bristol-Myers Squibb Company Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 7 weeks ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing


Bristol-Myers Squibb Company Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing


Bristol-Myers Squibb Company Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing


PhantomZ
PhantomZ Jun. 10 at 9:14 PM
$TLTFF $MRK $PFE $BMY https://medicalxpress.com/news/2026-06-ultrasound-anticancer-molecule-deep-lung.html
0 · Reply
Fingerlickengood
Fingerlickengood Jun. 10 at 4:17 PM
$CDXS $MRK $ALNY $BMY I believe the importance of this during their 2026 USA TIDES presentation was completely overlooked by focusing on 'stereo chemistry'. While the 'stereochemistry' aspect is important, this capability sets the EcoSynthesis Platform WELL AHEAD of any other existing and competing technologies! This alone will make it king, and the industry standard! https://www.codexis.com/technical-content/controlling-stereochemistry/
0 · Reply
Woodman7
Woodman7 Jun. 10 at 1:15 PM
$BMY $JNJ $ABT $PFIZER.NSE Check this Clene news
0 · Reply
Quantumup
Quantumup Jun. 9 at 7:06 PM
Raymond James says that w/ unanimous board approval, it sees no reason the $NUVL and $GSK M&A deal would not close in a timely manner—it thinks GSK is paying a fair price. ⬇️Nuvalent to Market Perform from Outperform $NUVB $BMY
0 · Reply
Quantumup
Quantumup Jun. 9 at 5:41 PM
RBC Capital sees pot'l readthrough to $NUVB (Outperform; $20) after $NUVL - $GSK M&A deal. $BMY Here's what RBC Capital had to say in its note to investors: https://x.com/Quantumup1/status/2064401843447276017?s=20
0 · Reply
taxplanr
taxplanr Jun. 9 at 12:33 PM
$BNTX $MRNA $MRK $BMY do you know why RNA programming will never work even for cancer? https://www.instagram.com/reel/DZLfm1EybwI/?igsh=b2ZiaG9vOGs5MXd0
1 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Jun. 8 at 7:11 PM
$PFE continues to make steady progress on a number of fronts as product lines expand and grow. Position into on weakness imho. Sector still weak and many big names performing poorly today $BMY $REGN $AMGN $BIIB for a few, but number of undervalued big names with solid dividends to boot!
1 · Reply
focafoca99
focafoca99 Jun. 8 at 11:32 AM
$BMY introduced its new multiple myeloma awareness campaign with Mariska Hargitay. https://www.rapidticker.com/news/bmy-mariska-hargitay-partners-with-bristol-ed2008
0 · Reply
CaesarZane
CaesarZane Jun. 7 at 9:13 PM
$GOOG $BMY $XOM 🚀🚀🚀 https://youtu.be/uk632v0svsY
0 · Reply
OnlyFibs
OnlyFibs Jun. 6 at 5:36 PM
$BMY is executing a masterful pipeline pivot. While the Street is stuck in "patent cliff" rearview-mirror thinking, the ASCO 2026 data shows mezigdomide is an absolute beast in multiple myeloma (52% progression risk reduction!). This isn't a legacy play anymore; it's a focused oncology innovator building high-margin durability. 🔬 🐂 Bull Level: Reclaim $57.00 to confirm the breakout toward $60.00+. 🐻 Bear Level: $54.00 is the non-negotiable floor. #BMY #BristolMyers #Oncology #Biotech #hovdid
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 5 at 5:57 PM
$BMY $PFE $SLS All the Big 5 Pharmaceuticals are green. Money rotation in to Pharmaceuticals bodes well for Sellas BO. ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 5 at 5:45 PM
0 · Reply
tony93
tony93 Jun. 5 at 2:51 PM
$BMY wants 58
0 · Reply
truehealthvalue
truehealthvalue Jun. 5 at 9:39 AM
$BMY I would look at $ELTX, About to take off, it will be worth billions in a short time
0 · Reply
biolover
biolover Jun. 5 at 6:07 AM
$VKTX  CEO confirmed high awareness of their obesity program across industry and high interest by BP .. essentially what we have been hearing from the likes of $ABBV $AMGN $NVO $BMY and likely others. Also his expectation for low GI issues with maintenance dosing in trial . Early cohort on this trial entered in Oct - Nov time line so good portion would have been already on monthly or q 2 wk dosing by now. Small trial and CEO should get timely reporting. This CEO has a history of giving clues as he hinted about higher GI issues with oral phase 2 ( turned out due to 4 large pills for 120 mg ) wks prior to reporting. Now he is upbeat on maintenance tolerability. Sounds like at least no vomit issue with first 21 wks despite more rapid escalation vs phase 3. ( I know there is no vomit issue with the vanquish program at more than one site as posted earlier ) I think all the slight delay with amylin likely to get oral amylin going. Based on his previous statements.
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 4 at 2:18 PM
$BMY 05 JUN 26 $58 CALL $0.15 CLINICAL TRIAL COLLAB + INSIDE BAR + RELATIVE STRENGTH + SECTOR HOT
0 · Reply
Blockwave1
Blockwave1 Jun. 4 at 2:17 PM
$BMY 🚨 05 JUN 26 $58 CALL $0.15 CLINICAL TRIAL COLLAB + INSIDE BAR + RELATIVE STRENGTH + SECTOR HOT
0 · Reply
Quantumup
Quantumup Jun. 4 at 12:03 PM
Citizens on $KURA: We reiterate our Market Outperform rating on Kura Oncology and price target of $24, based on a blended discounted EPS and revenue multiple analysis. $BMY SNDX AMGN ABBV - RHHBY $RVMD Here's what Citizens additionally said: https://x.com/Quantumup1/status/2062504701707370657?s=20
0 · Reply
Prady
Prady Jun. 3 at 10:31 PM
$BMY 70 soon
0 · Reply
Mitchell22
Mitchell22 Jun. 3 at 6:40 PM
$BMY Bristol Myers Squibb (BMS) offers medication savings through co-pay assistance for commercially insured patients and free medication programs for eligible uninsured or underinsured patients. Key options include BMS Access Support (1-800-861-0048) for co-pay cards and BMSPAF (1-800-736-0003) for the independent charitable foundation.
0 · Reply
TeresaTrades
TeresaTrades Jun. 3 at 1:32 PM
Largest CALL OI Increases $NU $DVN $INTC $BMY $ET
0 · Reply